Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Anna Nordenskjöld(Sahlgrenska University Hospital), Bo Nordenskjöld(Linköping University), Olle Stål(Linköping University), Helena Fohlin(Linköping University), Arne Wallgren(Sahlgrenska University Hospital), Henrik Lindman(Uppsala University), Tommy� Fornander(Karolinska University Hospital), Johan Rosell(Linköping University), Per Malmström, Lisa Rydén(Lund University), Nils‐Olof Bengtsson, Thomas Hatschek(Karolinska University Hospital)
Cited by 7
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
|British Journal of Cancer|2002|393
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260